TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01995383

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NS followed by LS diet condition
Description: NS diet period followed by LS diet period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NS followed by LS diet condition
Description: NS diet period followed by LS diet period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral administrations

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 single oral administrations

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 single oral administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6836191
Description: Orally administered, single ascending doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6836191
Description: 2 single oral doses
Study: NCT05805228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sexual Counseling
Description: Pregnancy and postpartum period-specific sexual counseling was given to pregnant women and their spouses.
Study: NCT01303679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV, 80mg/m² at d1, d8, d15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV, 10 mg/kg at d1, d15 or IV, 15 mg/kg every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: IV, 10 mg/kg at d1, d15 or IV, 15 mg/kg every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: daily 25 mg (1 pill) oral intake
Study: NCT00509431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib + Sirolimus
Description: In arm I of dose escalation phase,starting dose of erlotinib is 150 mg daily. Starting dose of sirolimus includes a 15 mg loading dose, followed by continuous dosing at 5 mg daily.Dose escalation will proceed according to protocol Phase II of the study was not conducted only Phase I
Study: NCT01995383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6836191
Description: 2 single oral doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RO6836191
Description: Intravenous administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RO6836191
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6836191
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6836191
Description: Intravenous administration
Study: NCT04018066

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GP-SPI
Description: grape polyphenol-soy protein isolate complex (GP-SPI)
Study: NCT04318197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized rehabilitation program with electrostimulation
Description: Patient with knee arthroplasty indication. After clinical assessment and a MRI measurement of muscle volume, patients start a 2 hours daily rehabilitation including 2 times 20 minutes of electrostimulation of atrophied muscles, 3 days per week during 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Global rehabilitation program
Description: Patient with knee arthroplasty indication. After clinical assessment and a MRI measurement of muscle volume, patient start a 2 hours daily rehabilitation targeting muscles groups with strengthening and stretching exercises, 3 days per week during 4 weeks.
Study: NCT02745288

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inferior alveolar nerve block
Description: A long acting local anaesthetic agent Inj Bupivacaine hydrochloride 0.5% (2 ml) will be given after induction by open mouth technique by landmark method.~The mucobuccal fold will be palpated and traced till coronoid notch. The finger will be moved medially across the retromandibular trigone on internal oblique ridge. The 25G needle will be inserted till bone is felt. 2 ml of 0.5% bupivacaine will be injected slowly after withdrawing needle by 1mm and confirming negative aspiration of blood.
Study: NCT02903979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HVGIC
Description: In experimental group, the researches will be performed a restoration, after partial caries removal, with high viscosity glass ionomer cement in the teeth with deep caries lesion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Indirect pulp capping
Description: In control group, the researches will be performed a indirect pulp capping with calcium hydroxide cement and high viscosity glass ionomer cement in the teeth with deep caries lesion.
Study: NCT03361046

Intervention type: DEVICE
Intervention: Transcatheter Aortic Valve-in-Valve Implantation (ViV-TAVI)
Description: Patients with failed aortic valve bioprostheses qualified for TAVI due to coexisting illnesses
Study: NCT04009616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aloe Vera mouthwash
Description: rinsing with aloe vera mouthwash for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Description: rinsing with chlorhexidine mouthwash for 5 days.
Study: NCT04199832

Intervention type: DIETARY_SUPPLEMENT
Intervention: Dietary guidance
Description: Dietary guidance for feeding tube patients with food homogenate，dietary guidance for patients with oral feeding.
Study: NCT04009616

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouthwash
Description: rinsing with placebo mouthwash for 5 days.
Study: NCT04330872

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric Coated Aspirin Tablet
Description: Study participants will be assigned to receive either EC Aspirin and will be required to continue taking them throughout the study (three days).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Plain Aspirin
Description: Study participants will be assigned to receive either Plain Aspirin and will be required to continue taking them throughout the study (three days).
Study: NCT02606812

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Traditional-food
Description: Intake of ethnic local food
Study: NCT04259333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 200mg
Description: Celecoxib tablet
Study: NCT04199832

Intervention type: DIETARY_SUPPLEMENT
Intervention: Dietary guidance
Description: Dietary guidance for feeding tube patients with food homogenate，dietary guidance for patients with oral feeding.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Dietary guidance
Description: Dietary guidance for feeding tube patients with food homogenate，dietary guidance for patients with oral feeding.
Study: NCT04259333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen, Codeine Drug Combination
Description: acetaminophen-codeine-caffeine tablet
Study: NCT04571593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Nidra
Description: The practice of Yoga Nidra, is a scripted and reproducible, guided meditation technique that promotes mental, emotional and physical relaxation while also facilitating the transition between waking and sleeping.
Study: NCT01543165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac and nefopam balanced analgesia
Description: Sequential intravenous administration of ketorolac and nefopam
Study: NCT04434573

Intervention type: OTHER
Intervention: Observation study
Description: French-speaking digestive surgeons are invited to respond to an online survey consisting of 13 common clinical situations concerning primary or asymptomatic incisional hernia pathology where a therapeutic decision is requested.
Study: NCT03488420

Intervention type: DRUG
Intervention: Edoxaban Pill
Description: Subjects will be taking edoxaban 30 or 60 mg
Study: NCT01543165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Balanced analgesia using ketorolac and morphine
Description: Sequential intravenous administration of ketorolac and morphine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pain control with single analgesics (ketorolac)
Description: This arm do not use balanced analgesia. Instead, ketorolac IV administration followed by 50cc normal saline administration (for blinding) will be used in this group.
Study: NCT02765035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Leg 4
Description: Microprocessor Controlled Knee

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Leg 4
Description: Microprocessor Controlled Knee

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Leg 3
Description: Microprocessor Controlled Knee
Study: NCT02461784

Intervention type: PROCEDURE
Intervention: Semen & Data Collection
Description: If participants decide to participate in this research they will be asked to complete the informed consent process as well as asked a few questions such as age and race/ethnicity. If participants volunteered for this study because tehy have IBD, investigators will also collect some information from the participants medical record. Completing this portion of participation will take less than 1 hour.~Participants will then be scheduled to complete the semen collection at the UW Health Generations Fertility Clinic located at 2365 Deming Way in Middleton, WI. This collection visit will take less than 1 hour to complete. Once participants have finished the collection visit they will have completed their participation in this research project.

Intervention type: PROCEDURE
Intervention: Semen & Data Collection
Description: If participants decide to participate in this research they will be asked to complete the informed consent process as well as asked a few questions such as age and race/ethnicity. If participants volunteered for this study because tehy have IBD, investigators will also collect some information from the participants medical record. Completing this portion of participation will take less than 1 hour.~Participants will then be scheduled to complete the semen collection at the UW Health Generations Fertility Clinic located at 2365 Deming Way in Middleton, WI. This collection visit will take less than 1 hour to complete. Once participants have finished the collection visit they will have completed their participation in this research project.
Study: NCT04670939

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: breath exercises
Description: diaphragmatic breathing exercise that used during weaning is the respiratory physiotherapy
Study: NCT00421954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: subjects will use ziprasidone
Study: NCT00677716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-chTNT-1/B MAb (Cotara)
Description: Given as a single interstitial infusion over approximately 25 hours at a dose of 2.5 mCi/cc.
Study: NCT00927030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: supplemental liquid melatonin
Description: Liquid melatonin will be given to the parent. There are 4 dose levels (1mg, 3mg, 6 mg, and 9mg)of melatonin that will be used at 3 week intervals. The child will start with 1mg and the dose will be increased at 3 week intervals until the child is falling asleep within 30 minutes of bedtime on 5/7 nights per week. Once this goal is reached the child will stay on that dose through the remainder of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: flavored liquid or liquid supplemental melatonin
Description: Single blind for parents at initial 3-weeks dose period of 1 mg melatonin for 18 children where 3/18 children will receive placebo and 15/18 children will receive melatonin study drug. Each bottle will be labeled as: Flavored liquid placebo/or liquid melatonin. After this initial 3-week period all children will receive known melatonin in bottles that state this.
Study: NCT02765035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Leg 3
Description: Microprocessor Controlled Knee
Study: NCT03095001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 5mg/kg intraperitoneal administration every 3 weeks for 4-6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC=5 intraperitoneal administration every 3 weeks 4-6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: carboplatin AUC=5 intraperitoneal administration every 3 weeks 4-6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel 175mg/m2, iv d1, every 3 weeks for 4-6 cycles
Study: NCT02301455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging
Description: persistently hypertensive participants will be randomized to receive these tailored, motivational text messages
Study: NCT04530071

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CordSTEM-DD (0.7 x 10^7 cells)
Description: CordSTEM-DD (0.7 x 10\^7 cells)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CordSTEM-DD (2.1 x 10^7 cells)
Description: CordSTEM-DD (2.1 x 10\^7 cells)
Study: NCT03095001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: paclitaxel 175mg/m2, iv d1, every 3 weeks for 4-6 cycles
Study: NCT04662099

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conditioning chemotherapy followed by CAR T cell infusion
Description: Conditioning chemotherapy: Cyclophosphamide 250 mg/m\^2 and fludarabine 30 mg/m\^2 IV infusion on days -5, -4, and -3 CAR T cells infusion: 0.75x10\^6-3.0X10\^6 CAR+ T cells per kg of recipient bodyweight. if DLTs don't occur at the dose of 3.0X10\^6 CAR+ T cells per kg, the investigators will discuss whether to try higher dose.
Study: NCT01487447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Customized sound
Description: treatment with customized sound therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Masker
Description: treatment with white noise
Study: NCT04530071

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: HA + saline + placebo comparator
Study: NCT00761098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard Care: 25% salt poor albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
Study: NCT01060579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-12286 0.5% ophthalmic solution
Description: q.d. PM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-12286 0.25% Ophthalmic solution
Description: q.d. PM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost ophthalmic solution
Description: q.d. PM
Study: NCT02135354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: * From day 1 up to and including day 3: 500 mg azithromycin PO once a day~* From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * From day 1 up to and including day 3: 500 mg placebo PO once a day~* From day 4 up to and including day 90: 250 mg placebo PO once every 2 days
Study: NCT00761098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental
Description: 25% Salt Poor Albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 only to those individuals with renal insufficiency and risk for renal failure.
Study: NCT04782141

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hand motor coordination in a sitting positin
Description: The subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was examined in adduction, with the elbow bent in the intermediate position between pronation and supination of the forearm. Wrist and a hand free from stabilization.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hand motor coordination in a supine position with the upper extremity positioned perpendicularly to the trunk
Description: motor tasks carried out in starting positions: supine with the upper extremity positioned perpendicularly to the trunk; the upper limb in adduction and flexion in the humeral joint, elbow extension, forearm in the intermediate position; elbow, wrist, hand free from stabilization.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hand motor coordination in a supine position with adduction in the humeral joint, elbow flexion in the intermediate position
Description: In the supine position, the upper limb was held beside the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position between pronation and supination of the forearm. Wrist and a hand free from stabilization.
Study: NCT01812187

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHIFT Cognitive Behavioral Therapy
Description: Manualized, evidence-based, cognitive behavioral therapy for the treatment of substance abuse disorders
Study: NCT01189448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrimethamine/Sulfadiazine
Description: Pyrimethamine + sulfadiazine group : Pyrimethamine 50 mg once daily orally and sulfadiazine 1g tid. orally, with supplemental folinic acid 50 mg once a week.~Follow-up includes clinical and biological tolerance, according to usual recommendations. Monthly fetal ultrasound is performed. Prenatal diagnosis with amniocentesis is offered after 18 weeks gestation, usually 4 weeks after the maternal infection.~Treatment is be stopped or changed in case of toxicity. If prenatal diagnosis shows fetal infection with T. gondii, management is to be determined by the clinicians with the patient. If the prenatal diagnosis is negative the treatment can be stopped in order to reduce the risk of intolerance, providing that the mother receives at least 4 weeks of therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spiramycine
Description: Spiramycin group : spiramycin 1g tid orally Follow-up includes clinical and biological tolerance, according to usual recommendations. Monthly fetal ultrasound is performed. Prenatal diagnosis with amniocentesis is offered after 18 weeks gestation, usually 4 weeks after the maternal infection.~Treatment is be stopped or changed in case of toxicity. If prenatal diagnosis shows fetal infection with T. gondii, management is to be determined by the clinicians with the patient. If the prenatal diagnosis is negative the treatment is continued according to usual procedures
Study: NCT02549196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.
Study: NCT02730962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin 3 times a day for 7 days
Study: NCT02549196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.
Study: NCT02730962

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills identical in appearance to each antibiotics to be taken on the same schedule as each antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neomycin
Description: Neomycin 3 times a day for 1 day
Study: NCT02549196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.
Study: NCT02730962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: Clindamycin 3 times a day for 5 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: FMT conducted via colonoscopy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: FMT conducted via colonoscopy
Study: NCT00988338

Intervention type: BIOLOGICAL
Intervention: Trinity Evolution
Description: Novel Allogeneic, Cancellous, Bone Matrix Containing Viable Stem and Osteoprogenitor Cells
Study: NCT02549196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.
Study: NCT00677638

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventor Embracer
Description: Implantation of Ventor Embracer
Study: NCT01612013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate plus saline
Description: Sodium bicarbonate solution (Sodium bicarbonate 8.4%, Equiplex, Brazil) was given by adding fifteen ampoules of sodium bicarbonate (150 mEq of sodium) to 1 L of 5% dextrose. Infusion in bolus began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous NAC plus saline
Description: Acetylcysteine (Flucistein 100 mg/ml, Neo Química, Brazil) was given via IV bolus at a rate of 150 mg/kg in 500 ml dextrose 5% over 60 min immediately before contrast exposure and followed by 50 mg/kg in 500 ml dextrose 5% during the contrast exposure and for 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
Study: NCT00543374

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROCHYMAL adult human mesenchymal stem cells
Description: intravenous infusion four times over two weeks; possibly repeated once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROCHYMAL adult human mesenchymal stem cells
Description: intravenous infusion four times over two weeks; possibly repeated once